Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has received an average rating of "Moderate Buy" from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $55.25.

Several research firms have issued reports on KYMR. HC Wainwright upped their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Citigroup initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price on the stock. UBS Group lowered their target price on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Stifel Nicolaus initiated coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price target on the stock. Finally, Bank of America cut their target price on Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating on the stock in a research note on Monday, May 12th.

Insider Buying and Selling

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. This represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This represents a 3.37% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,659 shares of company stock valued at $324,567. 16.01% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in KYMR. Northern Trust Corp raised its holdings in Kymera Therapeutics by 14.0% during the 4th quarter. Northern Trust Corp now owns 437,833 shares of the company's stock worth $17,614,000 after purchasing an additional 53,658 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Kymera Therapeutics by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after buying an additional 20,346 shares during the period. Victory Capital Management Inc. lifted its holdings in Kymera Therapeutics by 174.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock valued at $801,000 after buying an additional 12,643 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Kymera Therapeutics by 7.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock worth $1,163,000 after acquiring an additional 2,011 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Kymera Therapeutics by 51.8% during the 4th quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock worth $883,000 after acquiring an additional 7,487 shares during the period.

Kymera Therapeutics Stock Up 5.0%

KYMR stock traded up $1.45 during midday trading on Wednesday, reaching $30.25. 936,062 shares of the company's stock traded hands, compared to its average volume of 568,188. Kymera Therapeutics has a 1-year low of $19.45 and a 1-year high of $53.27. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -12.93 and a beta of 2.18. The company has a 50-day simple moving average of $28.70 and a two-hundred day simple moving average of $36.04.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. During the same period in the previous year, the firm posted ($0.69) earnings per share. The company's revenue was up 114.6% on a year-over-year basis. Equities research analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.